LAB News & Events

Reports Q4 revenue $23.8M, consensus $18.5M. "We delivered a strong finish to the year with better-than-expected performance, driven by disciplined execution across the business," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "Our team continued to deliver tangible efficiency gains, fully operationalizing over $40 million in previously announced cost savings and exiting the year with meaningfully lower run-rate operating expenses, reinforcing progress toward achieving our 2026 profitability targets."

For fiscal year 2026, the Company expects revenue in the range of $80 million to $85 million, with seasonality similar to prior years.

Standard BioTools (LAB) announced it has completed the previously announced sale of SomaLogic to Illumina (ILMN) for $350 million in upfront cash and up to $75 million in near-term earnout payments for aggregate cash consideration of up to $425 million plus specified royalties. "The closing of this transaction marks a major milestone in our strategic transformation. We are lean, focused and extremely well positioned, and emerge today far stronger than we were yesterday," said Michael Egholm, PhD, President and Chief Executive Officer of Standard BioTools. "We are now financially resourced to pursue disciplined M&A that accelerates growth and scale like few similarly sized peers in our industry can."

Standard BioTools announced preliminary and unaudited revenue results for the fourth quarter and full year 2025. Standard BioTools expects fourth quarter 2025 combined company revenue of approximately $56M and revenue from continuing operations of approximately $24M. For the full year 2025, the Company expects combined company revenue of approximately $185M and revenue from continued operations of approximately $85M. Our 2025 performance reflected steady execution, ending the year above our guidance range and exceeding expectations for both combined and continuing operations," said Michael Egholm, CEO. "Amid a shifting macro backdrop, the team remained focused - managing what we could control to drive the business forward. We continued our path toward profitability, taking targeted actions to streamline the organization and sharpen our operating model. Grounded in continuous improvement, we optimized workflows, improved our cost structure and drove rigor across the Company. These efforts strengthened our foundation and leave us exiting the year a leaner organization and a more resilient business. As we look to 2026, the sale of SomaLogic to Illumina remains on track to close in the first half of the year. At close, we expect to have approximately $550M in cash and a base business on its way to positive adjusted EBITDA - a combination that creates real strategic flexibility. With an experienced team, a simplified footprint and substantial cash, we are well positioned to pursue disciplined M&A as we work to build a diversified leader in life sciences."